Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib and Pembrolizumab plus TACE in Hepatocellular Carcinoma
NCT04246177Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- May 2020
- Primary completion
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 27
01
Overview
A Phase 3 trial of lenvatinib, pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Merck & Co.. Started May 2020; status: terminated.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04246177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04246177.